首页>投融资
NanoVation Therapeutics
战略投资
NanoVation Therapeutics 提供利用脂质纳米颗粒安全高效地输送核酸组织的技术。随着基因疗法的出现,我们正处于人类历史的关键转折点。在我们的有生之年,我们将看到由于这种新的治疗方法,重大疾病变得可以治疗或治愈。在NanoVation TherapeuticsTM (NTx),我们正在使这一未来成为现实,使基因药物能够安全有效地输送到体内的目标组织。我们的下一代平台技术使用脂质纳米颗粒将核酸输送到各种组织中。NTx针对特定靶点、有效载荷和给药途径开发可扩展的核酸鉴定脂质纳米粒子 (LNP) 配方。
基本信息
-
公司全称NanoVation Therapeutics Inc
-
类型基因疗法开发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址4th Floor, 2405 Wesbrook Mall, Vancouver
-
联系电话
-
邮箱
-
成立时间2020-01-01
投融资
-
2024-11-19战略投资未透露未透露
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem